Skip to Content
Merck
All Photos(1)

Documents

B0935

Sigma-Aldrich

Benazepril hydrochloride

≥98% (HPLC), solid

Synonym(s):

(3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H28N2O5 · HCl
CAS Number:
86541-74-4
Molecular Weight:
460.95
MDL number:
MFCD00895734
UNSPSC Code:
12352200
PubChem Substance ID:
24724409
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

solid

solubility

H2O: >5 mg/mL

originator

Novartis

SMILES string

Cl[H].CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CCc3ccccc3N(CC(O)=O)C2=O

InChI

1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1

InChI key

VPSRQEHTHIMDQM-FKLPMGAJSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Benazepril is a long-acting angiotensin converting enzyme (ACE) inhibitor.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 5

1 of 5

Captopril ≥98% (HPLC), powder

Sigma-Aldrich

C4042

Captopril

Spironolactone European Pharmacopoeia (EP) Reference Standard

S1200000

Spironolactone

Spironolactone United States Pharmacopeia (USP) Reference Standard

USP

1619006

Spironolactone

Lisinopril ≥98% (HPLC)

Sigma-Aldrich

L6292

Lisinopril

Leupeptin microbial, ≥90% (HPLC)

Sigma-Aldrich

L2884

Leupeptin

Yoshihiko Kanno et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 25(6), 939-943 (2002-12-18)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder in humans. Hypertension is one of the major complications, and its control might affect the renal survival and disease mortality. Suitable antihypertensive agents have been discussed based
Daphne P Bicket
American family physician, 66(3), 461-468 (2002-08-17)
When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were indicated only for treatment of refractory hypertension. Since then, they have been shown to reduce morbidity or mortality in congestive heart failure, myocardial infarction, diabetes mellitus, chronic renal insufficiency, and
A Salvetti et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 12(8), S91-S94 (1994-11-01)
SHORT- VERSUS LONG-ACTING ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS: Although ACE inhibitors are widely used in the treatment of hypertension, there are few data on trough:peak ratios and the data are contradictory. Part of the explanation for this lies in differences
Bjoern B Burckhardt et al.
Journal of pharmaceutical and biomedical analysis, 96, 118-126 (2014-04-18)
Although serum and plasma are the biological fluids of choice for pharmacokinetic determination of drugs in adults, it is desirable to elucidate noninvasive methods which can be used for investigations in vulnerable groups such as children. If the drug properties
Nadine Bongaerts et al.
Nature communications, 13(1), 3905-3905 (2022-07-08)
Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the pathogen's slow growth and biocontainment requirements. Here we present a synthetic biology framework for assaying Mtb drug targets in engineered E. coli. We construct Target Essential Surrogate E. coli
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service